Yacktman Asset Management LP Sells 36,184 Shares of Kenvue Inc. (NYSE:KVUE)

Yacktman Asset Management LP lowered its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 0.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,270,488 shares of the company's stock after selling 36,184 shares during the quarter. Kenvue makes up approximately 2.6% of Yacktman Asset Management LP's holdings, making the stock its 15th biggest position. Yacktman Asset Management LP owned about 0.43% of Kenvue worth $198,326,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KVUE. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Kenvue by 4.0% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company's stock worth $2,545,000 after buying an additional 4,034 shares in the last quarter. Steward Partners Investment Advisory LLC grew its position in shares of Kenvue by 143.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company's stock worth $1,023,000 after buying an additional 28,216 shares during the period. Starboard Value LP acquired a new position in shares of Kenvue during the 4th quarter worth about $467,864,000. TrueMark Investments LLC grew its position in shares of Kenvue by 9.3% during the 4th quarter. TrueMark Investments LLC now owns 190,595 shares of the company's stock worth $4,069,000 after buying an additional 16,161 shares during the period. Finally, Kingswood Wealth Advisors LLC acquired a new position in shares of Kenvue in the 1st quarter valued at approximately $413,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Stock Performance

Shares of NYSE:KVUE traded up $0.14 during midday trading on Thursday, reaching $20.90. 3,118,667 shares of the company traded hands, compared to its average volume of 16,091,111. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.63. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $25.17. The firm has a market capitalization of $40.09 billion, a price-to-earnings ratio of 37.99, a price-to-earnings-growth ratio of 3.22 and a beta of 0.83. The firm's fifty day moving average price is $22.51 and its two-hundred day moving average price is $22.31.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.01. Kenvue had a return on equity of 20.87% and a net margin of 6.90%. The business had revenue of $3.74 billion during the quarter, compared to analyst estimates of $3.69 billion. During the same quarter in the prior year, the firm earned $0.28 earnings per share. Kenvue's revenue for the quarter was down 3.9% on a year-over-year basis. On average, equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were issued a dividend of $0.205 per share. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.92%. Kenvue's dividend payout ratio is presently 149.09%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Citigroup reiterated a "neutral" rating on shares of Kenvue in a research note on Friday, June 13th. UBS Group increased their target price on Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Friday, May 9th. Evercore ISI began coverage on Kenvue in a research note on Monday, March 24th. They issued an "in-line" rating and a $25.00 price objective on the stock. Barclays increased their target price on Kenvue from $22.00 to $23.00 and gave the company an "equal weight" rating in a research report on Monday, May 12th. Finally, Redburn Atlantic assumed coverage on Kenvue in a research report on Thursday, April 10th. They issued a "neutral" rating and a $23.50 target price for the company. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $25.33.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.